A rrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

— Visirna Therapeutics, the Joint Venture formed by Arrowhead and Vivo, received an exclusive license in Greater China to four of Arrowhead’s RNAi-based investigational cardiometabolic medicines ...

VSA-003: Visirna Therapeutics VSA-003, is an investigational drug being developed by Visirna Therapeutics. The drug belongs to the class of Small interfering RNA. Currently the drug is in Phase I ...

BioWorld Content on 'Visirna Therapeutics'Arrowhead Pharmaceuticals Inc. and Vivo Capital LLC have launched a joint venture named Visirna Therapeutics for RNA interference therapeutics in the greater ...

Arrowhead Pharmaceuticals Inc. and Vivo Capital LLC have launched a joint venture named Visirna Therapeutics for RNA interference therapeutics in the greater China market. Arrowhead is the majority ...

Arrowhead Pharmaceuticals Inc. today announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines in Greater China. Funds ...